National Health (December 2025 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2025

Overview

The National Health (December 2025 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2025I, enacted on 27 November 2025, aims to address the statutory price reduction of a new brand of pharmaceutical item under the National Health Act 1953. This notifiable instrument was issued by Rebecca Richardson, Assistant Secretary of the Pricing and Policy Branch within the Department of Health, Disability and Ageing, acting as a delegate of the Minister for Health and Ageing. The policy objective underpinning this determination is to manage the pricing of new pharmaceutical brands in a manner that aligns with the approved ex-manufacturer price of existing brands, thus ensuring consistency and fairness in the pharmaceutical pricing framework. The determination specifies that the agreed price of the new brand of pharmaceutical item, detailed in Schedule 1, will be set equal to the approved ex-manufacturer price of the existing brand of the corresponding item, effective from 1 December 2025. This approach is designed to prevent any abrupt or disproportionate changes in pricing that could impact access to essential medications within the national health system. By doing so, the legislation seeks to maintain stability and predictability in the pharmaceutical market, ultimately supporting broader health policy goals.

Scope and Application

The National Health (December 2025 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2025 applies to the agreed price of specific brands of pharmaceutical items, particularly those listed in Schedule 1 of the instrument. The determination pertains to the brand of pharmaceutical items that are not subject to a price reduction, ensuring that the agreed price aligns with the approved ex-manufacturer price of existing brands. This determination is integral to the pricing framework established under the National Health Act 1953, which governs the pharmaceutical benefits scheme and related pricing policies. The application of this determination is national in scope, impacting all entities involved in the supply and pricing of pharmaceutical items within Australia. The determination does not explicitly state exclusions or thresholds, but it operates within the existing legislative framework and subordinate instruments of the National Health Act 1953. The authority for this determination is derived from subsection 99ACB(6A) of the Act, which empowers the Minister for Health and Ageing to exercise discretion in pricing matters. This instrument is effective from 1 December 2025, ensuring that the specified pharmaceutical brands are not subject to the statutory price reductions stipulated in the Act.

Key Provisions

The primary sections of the National Health (December 2025 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2025I outline the specific circumstances under which a new brand of pharmaceutical item will not be subject to a statutory price reduction (sections 1-5). Section 1 provides the name and citation of the instrument, while section 2 specifies the commencement date of 1 December 2025. Section 3 identifies the authority under which the determination is made, and section 4 clarifies definitions used within the instrument. Section 5 determines that the agreed price of the specified brand of pharmaceutical item will be equal to the approved ex-manufacturer price of the existing brand of the existing item. The obligations imposed by this determination on relevant parties include ensuring that the agreed price of the specified pharmaceutical brand aligns with the approved ex-manufacturer price of the existing brand. The Department of Health, Disability and Ageing, as represented by the Assistant Secretary, is tasked with enforcing this determination. Pharmaceutical companies and other relevant entities must adhere to the price set forth in the determination, ensuring that consumers do not face unexpected price changes. In the event of a breach of this determination, there may be both civil and criminal consequences. While the specific penalties are not detailed in the provided text, breaches of statutory determinations under the National Health Act 1953 can typically result in significant fines and, in severe cases, criminal charges. The maximum penalties would be in line with the provisions of the Act, which may include fines up to a specified amount and, in some instances, imprisonment. Legal action may also be pursued to enforce compliance and to rectify any non-compliance with the determination.